Kornimate/medical-research-clean huggingface dataset:
ivf outcome following progestogen ovarian stimulation

Conditions: IVF; Oocyte Maturation Defect 1; Clinical Pregnancy Rate; Ovarian Hyperstimulation

Summary: the new strategy is by using the progestogen to block the luteinizing hormone(lh) surge either endogenous during luteal phase stimulation, or exogenous in the follicular phase i.e progestin primed ovarian stimulation (ppos). the goal of ppos is to develop a single dominant follicle. various types of oral progestin had been studied before including medroxyprogesterone acetate (mpa) and utrogestan with different dosage. a different study by wang et al conducted by using mpa to patients with pcos. the use of mpa is contraindicated in human pregnancy whereas dydrogesterone had been extensively used worldwide for the treatment of threatened miscarriage as well as luteal support in infertility setting. previous protocol on ppos showed inconclusive results. therefore in this study, dydrogesterone was used as the progestin primed ovarian hyperstimulation to explore its effect on pcos women ivf outcome.

this is a prospective controlled cohort study conducted at the department of medical assisted conception (mac) unit of the university kebangsaan malaysia medical centre (ukmmc). from may 2018 through may 2019, women with polycystic ovarian syndrome (pcos) undergoing ivf/intracytoplasmic sperm insemination(icsi) regimens for the treatment of infertility were recruited. patients recruited will then be randomized accordingly using the randomizer software. group a will be the interventional group and group b will be the control group. oocyte retrieval will be performed 34-36 hours following the human chorionic gonadotrophin (hcg) trigger. sperm was obtained on the same day. mature oocytes will be fertilized with sperm via ivf or icsi. fertilized embryos were observed via time laps method and the progress and cleavage were monitored before planning for embryo transfer. embryo transfer will be performed on day 3 or day 5 after oocyte retrieval. all results will be analyzed using statistical package for the social sciences(spss) version 21 software. descriptive analysis will be done for demographic data and presented in mean ± standard deviation (sd). demographic characteristic between the two groups will be compared with the use of the mann-whitney u test. the categorical data was analysed by using chi-square test for the association of variables. a p-value of 0.05 or less was considered to be significant.

Eligibility criteria:
inclusion criteria: * · aged 20 - 40 years old * basal serum follicular stimulating hormone(fsh) level of no more than 10 iu/l * diagnosis of pcos met using rotterdam criteria. exclusion criteria: * low amh level (amh less than 3 ng/ml). * contraindicated to ovarian stimulation treatment eg: history of severe ovarian hyper stimulation syndrome(ohss) * presence of uterine pathology eg: adenomyosis, large uterine fibroid. * patients who has had poor ovarian stimulation of twice or more.

Keywords: progestogen ovarian stimulation regime ivf outcome
generative artificial intelligence nurse staffing study

Conditions: Burnout, Healthcare Workers

Summary: this study is guided by maslach's burnout theory and with normalization process theory supporting the implementation of the gains intervention by facilitating its integration into routine system-level practice. in year 1, the investigative team will collaborate with hospital-based nursing leadership and key stakeholders to identify staffing-specific factors essential for operationalizing the gains ai model/intervention. in year 1, the investigators will also conduct a survey amongst nursing staff to measure baseline burnout. in year 2, the ai-staffing intervention will be implemented with the medical-surgical nursing float pool team. in year 3, the investigators will first repeat the nurse burnout survey and second, expand the intervention to include the nursing assistant float pool team. in year 4, the investigators will conduct the final burnout survey with nurses, assess feasibility of gains (target vs. actual staffing- nurses and nursing assistants), and assess preliminary efficacy of gains to reduce costs related to staffing. the investigators will compare outcomes at three time points (pre, mid, and post-intervention). interviews with nurses, nursing assistants, unit nurse managers, and leadership will further explicate the intervention's acceptability, feasibility, and impact on burnout.


Eligibility criteria:
inclusion criteria: * registered nurses, nursing assistants, or key stakeholders * employed by the queen's medical center * working at least 24 hours per week * position associated with medical-surgical units where float pool nurses work exclusion criteria: * employees working less than 24 hours per week at the queen's medical center * employees whose roles are not related to medical-surgical units
serum and bronchoalveolar inflammatory parameters in patients with severe adult respiratory distress syndrome

Conditions: H1N1 Influenza

Summary: mannose-binding lectin (mbl) plays an important role in the innate immune response. in addition to activating the complement, mbl can induce cytokine production and contribute to a deleterious inflammatory response with severe a(h1n1)pdm09 virus infection. the aim was to determine if serum mbl levels correlate with the risk of mortality in intensive care units (icu) patients with a(h1n1)pdm09 infection. prospective observational study was performed in icu patients with acute respiratory distress syndrome due to influenza a(h1n1)pdm09 virus. demographic characteristics and severity indices were recorded at icu admission. mbl was assayed from blood drawn at influenza diagnosis within 24-48 h following the icu admission. outcomes were compared according to mbl levels.

mannose-binding lectin (mbl) plays an important role in the innate immune response. in addition to activating the complement, mbl can induce cytokine production and contribute to a deleterious inflammatory response with severe a(h1n1)pdm09 virus infection. the aim was to determine if serum mbl levels correlate with the risk of mortality in intensive care units (icu) patients with a(h1n1)pdm09 infection. prospective observational study was performed in icu patients with acute respiratory distress syndrome due to influenza a(h1n1)pdm09 virus. demographic and clinical data at admission and during the icu stay were recorded from the medical files of each patient and collected in a database to evaluate variables potentially associated with in-hospital mortality. data baselines were recorded at admission. mechanical ventilation, extracorporeal membrane oxygenation (ecmo) requirements, and the use of vasopressor drugs were noted during icu stay. to determine illness severity, sapsii and sofa scoring systems were applied to all patients within 24 h of icu admission.demographic characteristics and severity indices were recorded at icu admission. mbl was assayed from blood drawn at influenza diagnosis within 24-48 h following the icu admission. outcomes were compared according to mbl levels.

Eligibility criteria:
inclusion criteria: * patients who developed moderate-to-severe ards defined by the presence of bilateral alveolar images, a pao2 / fio2 ratio \<200 mmhg and the absence of an obvious cardiac cause, with or without the need for mechanical respiratory support extracorporeal circulation or decarboxylation. * patient benefiting from nitric oxide. * patient requiring continuous curarization. exclusion criteria: * chronic renal insufficiency dialysis. * severe hepatic insufficiency. * patient under guardianship or curatorship or deprived of liberty. * "light" ards

Keywords: pandemic influenza mortality icu
efficacy and safety study of ged-0507-34-levo for treatment of uc

Conditions: Ulcerative Colitis

Summary: this is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 doses of ged-0507-34-levo in subjects with active, mild-to-moderate uc.

this is a phase 2, proof of concept, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 doses of ged-0507-34-levo in subjects with active, mild-to-moderate ulcerative colitis. the study will consist of 3 phases: * screening phase - up to 4 weeks * double-blind placebo-controlled phase - weeks 0 to 8 * follow-up phase - week 9

Eligibility criteria:
inclusion criteria: * male or female aged 18 and over at the time of signing the informed consent. * diagnosis of uc with a duration of at least 3 months prior to the screening visit. * mms ≥ 4 to ≤ 8 (range: 0 - 9) prior to randomization in the study * subjects are required to have a colonoscopy if one has not been performed within 12 months prior to the screening visit. * subjects who have relapsed on maintenance therapy with doses of 5-asa ≤ 2.4 g/day exclusion criteria: * diagnosis of crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis, or diverticular disease-associated colitis. * uc restricted to the distal 15 cm or less (eg, ulcerative proctitis). * subjects who have had surgery as a treatment for uc or who, in the opinion of the investigator, are likely to require surgery for uc during the study. * clinical signs suggestive of fulminant colitis or toxic megacolon. * evidence of pathogenic enteric infection. * history of colorectal cancer or colorectal dysplasia. * prior use of any tnf inhibitor (or any biologic agent). * prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine, or thalidomide. * use of budesonide-mmx within the last 8 weeks. * use of oral and/or iv corticosteroids within 2 weeks of the screening visit. * use of immunosuppressants (azathioprine \[aza\], 6-mercaptopurine \[6-mp\] or methotrexate \[mtx\]) within 8 weeks of the screening visit.
polycystic ovary syndrome - improving outcomes

Conditions: Polycystic Ovary Syndrome

Summary: polycystic ovary syndrome affects a striking 9-18% of australian reproductive aged women and has been associated with a number of metabolic abnormalities. given the strong correlation between metabolic abnormalities and increased sympathetic activity, we hypothesise that reducing this activity using medication (moxonidine) can help improve the metabolic abnormalities, and therefore improve outcomes in polycystic ovary syndrome.


Eligibility criteria:
inclusion criteria: * overweight and class i obese pre-menopausal women * diagnosis of pcos by rotterdam criteria exclusion criteria: * any current medication * pregnancy or the desire to become pregnant * bmi \> 35 * a history of type i diabetes, secondary hypertension not due to pcos * cardiovascular, cerebrovascular, liver or thyroid disease * severe mental illness.

Keywords: polycystic ovary syndrome pcos sympathetic nervous system moxonidine
videolaryngoscopy versus direct laryngoscopy for endotracheal intubation of obese patients: a prospective randomized trial

Conditions: Intubating Laryngeal Airway

Summary: patients were randomly assigned (1:1) to either a macintosh laryngoscope group ("macintosh group") or a videolaryngoscope group ("video group").

in the macintosh group, intubation was performed with a standard curved macintosh blade. in the video group, intubation was performed with the assigned videolaryngoscope. if intubation proved difficult with the initially assigned device, anaesthesiologists could switch to the alternative method at their discretion (rescue technique).

Eligibility criteria:
• inclusion criteria: adult patients (\> 18 years) of both sexes with bmi \> 35 kg/m² scheduled for laparoscopic sleeve gastrectomy (asa \< iv). • exclusion criteria: * patient's refusal to participate. * known allergy to drugs used during anaesthesia. * chronic pain syndromes. * chronic opioid use.

Keywords: laryngoscopy tracheal intubation o besity patients , v ideolaryngoscopes
effects of parent-adolescent joint interventions for adolescents with adverse childhood experiences

Conditions: Stress, Emotional; Stress-related Mental Disorders; Adverse Childhood Experiences

Summary: the study aims to examine the effectiveness of joint parent-adolescent intervention in improving the mental health outcomes of participants, specifically by reducing symptoms of depression, anxiety, and ptsd, as measured by the patient health questionnaire (phq-9), the generalized anxiety disorder-7 scale (gad-7), and the child ptsd symptom scale for dsm-5 (cpss-5). adolescents will be recruited from middle schools and randomly assigned to one of three groups: (a) psychoeducation, (b) psychoeducation + emotional skills enhancement, or (c) psychoeducation + emotional skills enhancement + positive childhood experience promotion. the school-based intervention will consist of 4-8 sessions, with assessments conducted at baseline, post-treatment, and a 3-month follow-up. investigators will conduct multilevel models (mlms) and structural equation models (sems) to investigate the impact of adverse childhood experiences (aces), positive childhood experiences (pces), alexithymia, and emotion regulation abilities on mental health outcomes in adolescents.


Eligibility criteria:
inclusion criteria: * middle school students studying in school and their parents * capable of hearing, speaking, reading, and writing exclusion criteria: * high suicidal risks * severe mental disorders

Keywords: adolescents randomized controlled trial ptsd ace depression anxiety
a study to provide a better understanding of baraclude's pharmacokinetic properties in a real world clinical setting

Conditions: Hepatitis B Virus

Summary: a pharmacokinetics study of baraclude in a real world clinical setting in japan.


Eligibility criteria:
inclusion criteria: for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com. * participants with chronic hepatitis b (chb) (excluding participants with a superinfection) who have been confirmed to have chb. * participants who are being treated with 0.5 mg daily baraclude for a minimum of 10 consecutive days prior to the study enrollment. * body mass index (bmi) of 18.5 to 30 kg/m2 (bmi = body weight \[kg\]/height \[m\]2) exclusion criteria: * current or recent (within 3 months of baraclude administration) gastrointestinal disease that could impact upon the absorption of study drug. * any gastrointestinal surgery that could impact upon the absorption of study drug. * donation of blood to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration (within 2 weeks for plasma only). other protocol defined inclusion/exclusion criteria could apply.
retrospective review of the outcomes of newborns with genetic abnormalities

Conditions: Congenital Disorders

Summary: our hope is that the information from this retrospective study will provide information to better serve our patients and their parents with risk stratification (levels of risk) and clinical expectations of patients after cardiac surgery who have genetic abnormalities and those who do not have genetic abnormalities.

screening for genetic/chromosomal abnormalities has become more frequent both pre-natally and post-natally. therefore, we plan to review the outcomes in newborns with genetic abnormalities after cardiac surgery compared to those newborns without genetic abnormalities after cardiac surgery. we wish to examine the outcomes following cardiac surgery in newborns with genetic abnormalities compared to those newborns without genetic abnormalities. we will compare morality rates and co-morbidities in each group. we will retrospectively review the cardiac surgical database and patient medical records for all neonates (newborns \< 30 days of age) who underwent cardiac surgery from january 1, 2002 through may 31, 2006 at children's healthcare of atlanta. we plan to collect data on approximately 1000 patients including date of birth, age, weight, gestation, prenatal diagnosis, genetic abnormality, cardiac defect, surgery, operative details, pre-op and post-op complications, length of time on ventilator, hospital stay and mortality for these patients. we will review the patient outcome data available after their initial surgery through may 31, 2006. no patients will be contacted.

Eligibility criteria:
inclusion criteria: * neonates (newborns\< 30 days of age) * cardiac surgery between 1/1/02 - 5/31/06 * at children's healthcare of atlanta exclusion criteria: * those who do not meet inclusion criteria

Keywords: cardiac pediatric genetic
staccato apomorphine single and multi dose pk

Conditions: Parkinson Disease

Summary: this study will be conducted in 3 parts. a) compare the pharmacokinetics (pk) of a single dose of az-009 with that of a therapeutically-relevant dose of a commercially available apomorphine injector in healthy volunteers; b) ascending doses of active drug in healthy volunteers; and c) examine the tolerability, safety, and pk of az-009 in subjects with established parkinson's disease.

this study will be conducted in 3 parts. parts a and b will be conducted in healthy volunteers and part c will be conducted in subjects with established parkinson's disease. the primary objectives for each part are as follows. part a: to compare the pharmacokinetics of a single low dose of az-009 with that of a therapeutically-relevant dose a commercially available apomorphine injector in healthy volunteers. part b: to examine the tolerability and safety of az-009 of single ascending doses of active drug in healthy volunteers while; and to characterize the pharmacokinetics of single ascending doses of az-009 in healthy volunteers part c: to examine the tolerability, safety, and pharmacokinetics of az-009 in subjects with established parkinson's disease and to identify optimal doses to bring into multiple ascending dose safety and efficacy studies; and to assess the usability of az-009 in subjects with parkinson's disease

Eligibility criteria:
inclusion criteria: * healthy adult males and females between 18 and 60 years of age, inclusive at the time of signing the informed consent document. * body weight ≥ 50 kg and bmi within the range of 18 to 32 kg/m2. * willing and able to be confined at the clinical research center for the study period and adhere to overall study visit schedule, procedures and other protocol requirements. * understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted. exclusion criteria: * any significant medical condition, psychiatric illness or history of depression that could, in the investigator's opinion, compromise the subject's safety or interfere with the completion of this protocol. * history of clinically significant central nervous system, cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions including gastric bypass or other weight loss surgical procedure; or history of such conditions that, in the opinion of the investigator, may place the subject at an unacceptable risk as a participant in this trial. * use of non-prescription medications within 5 days prior to the first dose of study drug. * use of medication that is inhibitor or inducer of cyp450-3a4/5 within 3 days of dosing. * consumption of grapefruit, grapefruit juice, star fruit, oranges, orange juice, seville oranges, within 3 days prior to administration of study drug.

Keywords: apomorphine aerosol
analgesic efficacy of ultrasound guided erector spinae block for modified radical mastectomy

Conditions: Pain, Postoperative

Summary: to compare the analgesic efficacy of dexmedetomidine and magnesium sulphate as adjuvants to levobupivacaine in erector spinae plane block in modified radical mastectomy surgery for acute and chronic pain management.

3 groups. group (c) / (i):20 patient (control group) : patients will receive 20 ml 0.25% levobupivacaine into the interfascial plane below erector spinae muscle at level of t5. group (d)/ (ii) :20 patient (dexmetonidine group) : patient will receive 20ml 0.25% levobupivacaineas above + 1μ/kg dexmedetomidine. group (m) / (iii) : 20 patient (magnesium slphate group) : patient will receive 20ml 0.25% levobupivacaineas above + 0.7 mg/kg mgso4 . the patient, the anesthesiologist who administered the drugs, and the data collector will be blinded to the study drugs.

Eligibility criteria:
inclusion criteria: * female patient * american society of anesthesiologists (asa) i and ii physical status * age from 25 to 70 years old * scheduled for either left or right modified radical mastectomy (mrm). exclusion criteria: * infection of the skin at or near site of needle puncture * coagulopathy * drug hypersensitivity or allergy to the studied drugs * central or peripheral neuropathy * significant organ dysfunction cardiac dysrrhythmias * obesity (bmi\>35kg/m2) * recently use analgesic drugs

Keywords: erector spinae block magnesium sulphate dexmedetomidine
effect of simultaneous application of hd-tdcs and robot-assisted gait training on gait function in stroke patients

Conditions: Stroke

Summary: the purpose of this study was to investigate the effects of simultaneous application of transcranial direct current stimulation (tdcs) with robotic gait training in stroke patients with gait impairment.


Eligibility criteria:
inclusion criteria: * age: 19 - 79 years * more than 3 months post stroke * functional ambulation classification (fac) (1\~4) exclusion criteria: * history of serious neurological disease other than stroke * difficult to understand experimental tasks because of extremely severe cognitive impairment (korean-mini-mental state examination, k-mmse≤10) * history of psychiatric disease * contraindicated to tdcs
ketoconazole in treating participants with ongoing egfr inhibitor-induced rash

Conditions: Malignant Neoplasm

Summary: this early phase i trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing egfr inhibitor-induced rash. ketoconazole may reduce the symptoms related to egfr inhibitor therapy and improve egfr inhibitor-induced rash.

primary objectives: i. to demonstrate that topical ketoconazole, an anti-androgen, palliates egfr inhibitor-induced rash within a group of racially diverse cancer patients. ii. to explore the role of ribonucleic acid (rna) sequencing to identify other targets that might be used at a later date for rash palliation. iii. to evaluate toxicities associated with topical ketoconazole. outline: participants are randomized to 1 of 2 arms. arm i: participants apply ketoconazole topically twice daily (bid) on days 1-28. arm ii: participants apply placebo topically bid on days 1-28. after completion of study treatment, participants are followed up at 1 week.

Eligibility criteria:
inclusion criteria: * patient has developed a rash or symptoms of a rash (cutaneous burning) characteristic of an egfr inhibitor (health-care provider report of the rash with no other documentation is permitted) * patient is anticipated to continue for at least 28 days with an egfr inhibitor or restart =\< 14 days of registration and continue for at least 28 days * mayo only: patient is willing to provide a skin biopsy for correlative research; note: can be waived with permission of study chair (documentation such as an email must be provided) * patient must complete baseline quality of life (qol) packet exclusion criteria: * patient has a prior allergy or intolerance of ketoconazole * patient has an allergy or intolerance to sulfites